ABBOTT PARK, Ill., January 21, 2010. - The Committee for Medicinal Products for Human Use (CHPM) within the European Medicines Agency (EMA) has issued a recommendation to suspend the marketing authorisation of all anti-obesity drugs containing sibutramine. Abbott will comply with the CHPM's recommendation and suspend marketing of Abbott-manufactured drugs containing sibutramine in all European Union member states, as well as in Iceland and Norway, which are part of the European Economic Area. Abbott manufactures sibutramine under the trade names Reductil, Meridia, Sibutral, Ectiva and Raductil.